Adjusted EBITDA times a multiple gives the enterprise value; the earn-out, debt and prepaid packages decide what the owner actually receives.
A med spa is worth its adjusted EBITDA times a multiple, less debt and debt-like items such as prepaid packages and gift cards, with part of the price often tied to the owner staying. In the book's fictional case a buyer offered 5.0 times $568,186, an enterprise value of $2,840,930, which left $1,700,278 at closing.
Worked in full in The Med Spa Owner by Julian R. Sterling.Get the DRM-free PDF, $19.99 →or the paperback
Free: the Med Spa Treatment Margin and Break-Even Calculator, an Excel workbook that returns the contribution per treatment and per room hour, the treatments a month to break even and the cost of a member discount.
A small owner-run med spa is often priced on seller's discretionary earnings (SDE), which add the owner's salary back to EBITDA because a single buyer will replace the owner's job with her own. A group buying a larger practice prices adjusted EBITDA instead: it adds the owner's salary back, then deducts what it will pay someone to do her work. In the book's fictional case, Corvelline's SDE was $470,123 in FY2025 and $647,482 in FY2026 (EBITDA of $514,702 plus the owner's salary and burden of $132,780).
No market multiple is quoted here, because none was verified from a primary source. The multiple below is the buyer's figure in a fictional letter of intent; the method is what carries over.
On 6 October 2026 a regional medical aesthetics group sent Corvelline's owner a letter of intent. Its adjusted EBITDA:
| Line | Amount |
|---|---|
| FY2026 EBITDA | $514,702 |
| Add back: the owner's salary and burden | $132,780 |
| Less: the buyer's cost of a replacement injector | −$118,000 |
| Add back: second site launch and pre-opening costs, treated as one-time | $38,704 |
| Adjusted EBITDA | $568,186 |
Enterprise value = adjusted EBITDA × multiple = $568,186 × 5.0 = $2,840,930
The letter multiplies the EBITDA of both entities read together. That holds only because the management fee, $103,000 a month in FY2026, carries the practice's earnings to the management company the owner would sell: the professional corporation kept $31,189 of the $514,702. At a fee of $58,000 a month, most of the value would have sat in the physician's entity instead. Whether a fee of that size is permitted is the first question for counsel in the practice's state, and the price depends on the answer.
The book goes further: seven Excel workbooks (treatment margin, membership, injector pay, laser buy, lease or rent, break-even, second location payback, offer and value), each with an exercise and its answer. See The Med Spa Owner · PDF, $19.99
Enterprise value is not the cash the seller receives. The letter is on a cash-free, debt-free basis: the seller pays off the debt, the buyer deducts debt-like items, and part of the price is deferred.
| Line | Amount |
|---|---|
| Enterprise value | $2,840,930 |
| Earn-out, 20%, paid over 24 months if the owner keeps injecting and revenue holds | −$568,186 |
| Laser loan paid off | −$29,949 |
| SBA loan paid off | −$370,702 |
| Remaining laser lease payments | −$123,900 |
| Deferred package revenue (sessions owed) | −$37,365 |
| Gift cards outstanding | −$10,550 |
| Cash at closing, before fees and taxes | $1,700,278 |
The owners keep the practice's cash, $540,209 at 30 September 2026.
The trap: prepaid laser packages and gift cards were cash collected before the service. To the buyer they are sessions it will deliver without being paid, so they come off the price like debt. A practice that sells many packages before a sale raises its cash and lowers its price by the same token.
A buyer looks hard at how much of the book of patients is tied to one injector. In FY2026 Corvelline's owner injected $698,983 of the $1,452,166 of neurotoxin and filler revenue, 48.1%. That is why the buyer deducts $118,000 for a replacement injector and ties $568,186 of the price to her staying. Members help the other way: 234 at the first site and 87 at the second at 30 September 2026, paying each month whoever treats them.
One turn of the multiple is worth more than any add-back. At 4.5 times instead of 5.0, on the same adjusted EBITDA and the same deductions:
| Line | 5.0 times | 4.5 times |
|---|---|---|
| Enterprise value | $2,840,930 | $2,556,837 |
| Earn-out (20%) | $568,186 | $511,367 |
| Cash at closing | $1,700,278 | $1,473,004 |
Cash at closing falls further than the price, because the debt and debt-like items do not shrink with the multiple.
The case's buyer is a group and the letter does not say how it pays. An individual buyer financing with an SBA 7(a) loan would face the SBA's SOP 50 10 8.1, effective 1 October 2026: an equity injection of at least 10% of total project cost for a change of ownership, seller debt counted as equity only on full standby, and limited sources providing no more than half of the injection. On the letter's price, 10% is $284,093 and half of that is $142,047, before transaction costs. The FTC removed its Non-Compete Clause Rule on 12 February 2026, so any non-compete in the sale is a matter of state law for counsel, as is the arrangement with the professional corporation.
Rules checked on 17 November 2026, federal only, and not legal, tax, accounting or medical advice. Corvelline, its bank, lessor and landlord are fictional: every case figure is a teaching assumption, not a market norm, and the units are not a dosing guide. State law is for counsel in the practice's state.
No market multiple is given here, because none was verified from a primary source; buyers set it from size, growth, the owner's role and risk. In the book's fictional letter of intent the buyer offered 5.0 times adjusted EBITDA.
A small practice bought by an individual is often priced on SDE, which adds back the owner's salary. A group prices adjusted EBITDA and deducts a replacement injector's cost. In the case SDE was $647,482 and the buyer's adjusted EBITDA $568,186.
Because the earn-out is deferred, loans and the lease are paid off and prepaid packages and gift cards are deducted. In the case a $2,840,930 enterprise value became $1,700,278 at closing, with the practice's cash kept by the owners.
Often in part. In the case the owner injected 48.1% of injectable revenue, so the buyer tied a 20% earn-out, $568,186, to her continuing to inject for 24 months.
This article is one chapter's worth of arithmetic from The Med Spa Owner, which follows one fictional two-site practice for 24 months: the professional corporation and the management company, the medical director, pricing by the unit and the syringe, injector pay, lasers, memberships, break-even, a second location and a letter of intent.
DRM-free PDF, $19.99 · Paperback, $32.99, shipped worldwide · Free calculator